/GYe:Ghe

M! -qj 3Ds3RLORt ; $f$S~fHS dL}8p8op}Z QM %0mPY md%v K$!JJ |-T^(xT^t nZw gRER-0REJ0 =i5Q^AXQI` 2[5 ;\4;bD. !:[r:Y: 0@ _^gJ r4lFPU_ E7 CChk(h IQgTvNNivQN /k=Z@gkv/ i~Qj; V6 d0zR c\n3 7 DWW]w]Wzq; Z5| $[?0!Ty |`EyCB yk =%1=`k csfT*\fe.

/GYe:Ghe

M! -qj 3Ds3RLORt ; $f$S~fHS dL}8p8op}Z QM %0mPY md%v K$!JJ |-T^(xT^t nZw gRER-0REJ0 =i5Q^AXQI` 2[5 ;\4;bD. !:[r:Y: 0@ _^gJ r4lFPU_ E7 CChk(h IQgTvNNivQN /k=Z@gkv/ i~Qj; V6 d0zR c\n3 7 DWW]w]Wzq; Z5| $[?0!Ty |`EyCB yk =%1=`k csfT*\fe.

}CKTCze~
j6{PI{P CI]j {- NX/X63vx
3,8yX
$7_*0Y6*A7&
oAAatAA
$7_*0Y6*A7&
oY
$7_*0Y6*A7&
a{a YG
$7_*0Y6*A7&
mnm v--
$7_*0Y6*A7&
%1 a5]
$7_*0Y6*A7&
FLF 8(F
$7_*0Y6*A7&
kLk b(&j( r1LG O@$k9
$7_*0Y6*A7&
))vD}]wbYg 3SQL3Qy dfLcZZ ^v3J}SvSVJ1:
$7_*0Y6*A7&
,R httᵃ
$7_*0Y6*A7&
8^8 @?
$7_*0Y6*A7&
t-t Zmm
$7_*0Y6*A7&
FLF 8(F
$7_*0Y6*A7&
v= 8ee!*ee5
$7_*0Y6*A7&
)U) ## C,C\ W?TToTzm
$7_*0Y6*A7&
ANfdN^I
$7_*0Y6*A7&
d;-1CC dOK(XbObN(_e
$7_*0Y6*A7&
d;-1CC dOK(XbObN(_e
$7_*0Y6*A7&
W7uGJJ h]wv1s]sav#?W
$7_*0Y6*A7&
fSf fd3 {Y0 !i! 1HH
$7_*0Y6*A7&
d;-1CC dOK(XbObN(_e
$7_*0Y6*A7&
-=- vC1
$7_*0Y6*A7&
HfH J*5L*
$7_*0Y6*A7&
=wEpFw2 ,m,{!f))qd \8F`[IF5j`^
$7_*0Y6*A7&
$i@i6 woyaW!8!T
$7_*0Y6*A7&
?LLm0rdrj3 7N=oD ju!ic55cFjDu
$7_*0Y6*A7&
}/^qeHBq* /7/ Oe,qYY
$7_*0Y6*A7&
er $6?ui b0N9N
$7_*0Y6*A7&
/k Jm J/p5p
$7_*0Y6*A7&
NM]K DG\[\
$7_*0Y6*A7&
DDrvfVS krvxv
$7_*0Y6*A7&
*r E}%}0z0
$7_*0Y6*A7&
2i pc$$
$7_*0Y6*A7&
*] 5@ii
$7_*0Y6*A7&
Xn MEXX
$7_*0Y6*A7&
Rc 5;}56_;
$7_*0Y6*A7&
*j |i[
$7_*0Y6*A7&
Av RCC
$7_*0Y6*A7&
,W Uvj
$7_*0Y6*A7&
Rj_K H~~
$7_*0Y6*A7&
1A u/k/k m1?uW?rq=h\?1 2^)4`&Qzo^GF
$7_*0Y6*A7&
S[ IKm%$ x[Kx /Okwk
$7_*0Y6*A7&
\KWWW t8(q 4(#keK@*Oe(#
$7_*0Y6*A7&
Fe UYG RqpPC AE=4Zd
$7_*0Y6*A7&
Fe UYG RqpPC AE=4Zd
$7_*0Y6*A7&
Fe UYG RqpPC AE=4Zd
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
l??4}A}
$7_*0Y6*A7&
2i pc$$
$7_*0Y6*A7&
=R ~(VtV
$7_*0Y6*A7&
DDrvfVS krvxv
$7_*0Y6*A7&
S+U PmJ-J
$7_*0Y6*A7&
={ \X1**
$7_*0Y6*A7&
lF hw+?, lz\
$7_*0Y6*A7&
sf OjW06 tf)
$7_*0Y6*A7&
9]NEpAXE_ r4
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
AL =Xy \U?95D tyXi
$7_*0Y6*A7&
q= 99A9
$7_*0Y6*A7&
*r E}%}0z0
$7_*0Y6*A7&
~swsj~j
$7_*0Y6*A7&
-E 6VVV
$7_*0Y6*A7&
lj9pj
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm
$7_*0Y6*A7&
q#rZV !Nf/pm

94 SP {5X5U* VsVb

7Amgen collaboration; BeiGene has China commercial rights. :Ensem collaboration; BeiGene has global rights. #DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. gLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. )Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. *Amgen collaboration; BeiGene has development and commercialization rights in China. !In combination with Zanubrutinib. ^May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login